We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -0.14% | 35.55 | 35.60 | 36.05 | 36.50 | 35.55 | 36.45 | 350,596 | 16:15:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.32 | 106.9M |
From Apr 2019 to Apr 2024
TIDMFUM
RNS Number : 9991J
Futura Medical PLC
04 July 2017
For immediate release 4 July 2017
Futura Medical plc
("Futura" or the "Company")
Investor Presentation on MED2002
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that the Company is today presenting to institutional investors on its topical gel for erectile dysfunction, MED2002.
MED2002 represents a breakthrough treatment for erectile dysfunction ("ED") with the potential to offer the fastest speed of onset, the least side-effects and the fewest contra-indications of any ED medication.
Today's presentation is based on the presentation that Futura gives to potential licensing partners and comprises a detailed insight into key aspects of the clinical development and commercial potential of the product.
The presentation is taking place at noon today at the Surrey Research Park, where Futura is based, as part of a capital markets event organised by N+1 Singer, the Company's nominated adviser and broker.
A copy of the slide deck accompanying the presentation is now available at the investor section of Futura's website, www.futuramedical.com.
No new price sensitive information will be disclosed.
For any further information please contact:
Hot Features
Premium
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0)1483 685
670
mail to: james.barder@futuramedical.com www.futuramedical.com
N+1 Singer (Nominated Adviser
and Broker)
Aubrey Powell / Liz Yong Tel:+44 (0) 20 7496 3000
For media enquiries please
contact:
Buchanan
Mark Court / Sophie Cowles Tel: +44 (0)20 7466 5000
/ Stephanie Watson
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCRJMLTMBBMBLR
(END) Dow Jones Newswires
July 04, 2017 02:00 ET (06:00 GMT)
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
